Should You Avoid Neurocrine Biosciences, Inc. (NBIX)?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We...
Posts Tagged ‘NASDAQ:NBIX’
Hedge Funds Aren’t Crazy About Neurocrine Biosciences, Inc. (NBIX) Anymore
Coronavirus is probably the #1 concern in investors’ minds right now. It should be.
How Did Neurocrine Biosciences, Inc. (NBIX) Compare Against Top Hedge Fund Stocks in 2019?
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing.
Hedge Funds Have Never Been This Bullish On Neurocrine Biosciences, Inc. (NBIX)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through November 22nd.
Were Hedge Funds Right About Piling Into Neurocrine Biosciences (NBIX)?
A whopping number of 13F filings filed with U.S.
Hedge Funds Are Dumping Neurocrine Biosciences, Inc. (NBIX)
There are several ways to beat the market, and investing in small cap stocks has historically been one of them.
Did Hedge Funds Drop The Ball On Neurocrine Biosciences, Inc. (NBIX) ?
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons.
Should You Buy Neurocrine Biosciences, Inc. (NBIX)?
During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ...
13G Filing: Perceptive Advisors and Neurocrine Biosciences Inc (NBIX)
Please follow Perceptive Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Perceptive Advisors or update its stock holdings...
Check Out These 34 Stories To Find Out What’s Happening In The Financial Markets Today
"U.S. equities traded higher on Wednesday as investors cheered the Federal Reserve's plan for scaling back its massive $4.5 trillion balance sheet.
Neurocrine Biosciences, Inc. (NBIX) Surges After FDA Gives Green Light to Ingrezza
Shares of Neurocrine Biosciences, Inc.
Here Are Two Market Moving Biotech Catalysts To Watch This Week
The biotechnology sector is in full swing for the New Year, and while the JP Morgan conference is now in the rearview mirror, there are still plenty of potential catalysts set...
What Does The Panel Cancellation Mean For Neurocrine Biosciences, Inc. (NBIX)?
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) just announced that that the FDA has cancelled the Psychopharmacologic Drugs Advisory Committee meeting for INGREZZA.
Is Neurocrine Biosciences, Inc. (NBIX) a Good Stock to Buy?
It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity.
Big Bet on Sarepta Therapeutics Inc (SRPT) Lifts Perceptive Advisors’ Q3 Returns; See How Other Investments Performed
Joseph Edelman's Perceptive Advisors is a fund that has an equity portfolio worth $1.44 billion as of the end of June, with over 80% of it being invested in healthcare stocks.
This Biotech Hedge Fund’s Stock Picks Killed It in Q3
Hedge funds returned about 4% so far this year and underperformed the S&P 500 Index again.
Here’s Our Take On Neurocrine Biosciences, Inc. (NBIX)’s Ingrezza
Neurocrine Biosciences, Inc.
Blue Jay Capital Betting On Big Returns From These Healthcare Stocks
Founded by Paul Sinclair in August 2014, Blue Jay Capital Management is a healthcare-focused hedge fund based in California.
Top Biotech Picks of Best-Performing Hedge Fund of 2015
Bloomberg recently came out with its list of best performing hedge funds of 2015 and the fund that managed to beat all its rivals and emerge at the top of the list was biotech...
Four Stocks Driving Thursday’s Market Gains: How Did They Do It?
In the first eight days of the year, the S&P 500 index fell by roughly 7.5%, the Dow lost 7.3%, and the NASDAQ tumbled by 9.6%.
Hedge Funds Growing Fond Of Neurocrine Biosciences, Inc. (NBIX)
Is Neurocrine Biosciences, Inc. (NASDAQ:NBIX) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research.
Amicus Therapeutics, Inc. (FOLD), Neurocrine Biosciences, Inc. (NBIX), and Retrophin Inc (RTRX) among Biotech Guru Joseph Edelman’s Top Healthcare Picks
Biotech Guru Joseph Edelman's Perceptive Advisors is known for its long-short investment approach that focuses on biotech stocks.
More Than 60% Returns For These Two Hedgies’ Favorite Health Care Picks
The health care sector has appreciated by nearly 30% over the past year. We decided to take a look at three companies that two health care-focused funds, namely James A.
Is Pacira Pharmaceuticals Inc (PCRX) Going to Burn These Hedge Funds?
To the average investor, there are many methods market participants can use to analyze publicly traded companies.
Neurocrine Biosciences, Inc. (NBIX), ChemoCentryx Inc (CCXI), Avanir Pharmaceuticals, Inc. (AVNR): Horrendous Health-Care Stocks Last Week
In a way, stocks go through seasons like the weather. Sometimes they spring forth, sometimes they're hot like summer, sometimes they're dormant and cold like winter.
GlaxoSmithKline plc (ADR) (GSK), Inovio Pharmaceuticals Inc (INO), ISIS Pharmaceuticals, Inc. (ISIS): This Week in Biotech
With the SPDR S&P Biotech Index up 40% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Why Neurocrine Biosciences, Inc. (NBIX) Shares Imploded
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
AbbVie Inc (ABBV), AstraZeneca plc (ADR) (AZN): Neurocrine Biosciences, Inc. (NBIX) Nosedives on Mid-Stage Study Results
Investors hate to wake up and find that one of their stocks has opened nearly 30% lower than the prior day's close.
This Metric Says You Are Smart to Buy Neurocrine Biosciences, Inc. (NBIX)
In the financial world, there are dozens of indicators investors can use to track publicly traded companies. Two of the best are hedge fund and insider trading movement.
Hedge Funds Are Buying Impax Laboratories Inc (IPXL)
At the moment, there are tons of indicators shareholders can use to analyze publicly traded companies.
Hedge Funds Aren’t Crazy About Rigel Pharmaceuticals, Inc. (RIGL) Anymore
In the eyes of many investors, hedge funds are seen as useless, outdated investment tools of a forgotten age.
Is Aegerion Pharmaceuticals, Inc. (AEGR) Going to Burn These Hedge Funds?
To the average investor, there are dozens of gauges market participants can use to watch publicly traded companies.
Here is What Hedge Funds Think About Pacira Pharmaceuticals Inc (PCRX)
Is Pacira Pharmaceuticals Inc (NASDAQ:PCRX) a superb investment right now? Hedge funds are in an optimistic mood.
Neurocrine Biosciences, Inc. (NBIX): Are Hedge Funds Right About This Stock?
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was in 16 hedge funds' portfolio at the end of the first quarter of 2013.
Hedge Funds Are Betting On Rigel Pharmaceuticals, Inc. (RIGL)
According to most shareholders, hedge funds are seen as unimportant, outdated investment vehicles of years past.
Here is What Hedge Funds Think About Neurocrine Biosciences, Inc. (NBIX)
In the financial world, there are a multitude of methods market participants can use to monitor publicly traded companies.
Hedge Funds Are Buying Aegerion Pharmaceuticals, Inc. (AEGR)
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) was in 14 hedge funds' portfolio at the end of the fourth quarter of 2012.
Is Aegerion Pharmaceuticals, Inc. (AEGR) Going to Burn These Hedge Funds?: Impax Laboratories Inc (IPXL), Pacira Pharmaceuticals Inc (PCRX)
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) was in 14 hedge funds' portfolio at the end of December.
Endocyte, Inc. (NASDAQ:ECYT), Kythera Biopharmaceuticals Inc (NASDAQ:KYTH): Should You Avoid Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)?
To most stock holders, hedge funds are seen as unimportant, old financial vehicles of the past.
Aetna Inc. (AET), Rosetta Stone Inc (RST) & More: Three Stocks Near 52-Week Highs Worth Selling
Yesterday's Automatic Data Processing (NASDAQ:ADP) employment data may not have struck a chord with optimists, and North Korean tensions appear to be escalating, but that didn...
Hedge Funds Aren’t Crazy About Neurocrine Biosciences, Inc. (NBIX) Anymore: Keryx Biopharmaceuticals (KERX), Rigel Pharmaceuticals, Inc. (RIGL)
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was in 12 hedge funds' portfolio at the end of December.
3 Humongous Health-Care Stocks This Week: Dendreon Corporation (DNDN), Neurocrine Biosciences, Inc. (NBIX)
As millions of Americans brace themselves for a massive blizzard, a handful of health-care stocks have been heating up the charts over the past few days.
